WAY-262611 is acting via the Wnt β-catenin pathway and most likely through inhibition of Dkk-1. WAY-262611 has excellent pharmacokinetic properties and showed a dose dependent increase in the trabecular bone formation rate in ovariectomized rats following oral administration.
产品描述
WAY-262611 is a wingless β-Catenin agonist that increases bone formation rate; with EC50 of 0.63 uM in TCF-Luciferase assay